PF
Patricia F. Walker, M.D., Ph.D.
Chief Scientific Officer & Head of Translational Science
Oculis Holding AGTherapeutic Areas
Oculis Holding AG Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCS-01 | Diabetic Macular Edema (DME) | Phase 3 |
| Licaminlimab (OCS-02) | Dry Eye Disease (DED) | Phase 2/3 |
| Privosegtor (ACT-01) | Optic Neuritis | Phase 2 |
| OCS-02 | Acute Anterior Uveitis | Phase 2 |
Leadership Team at Oculis Holding AG
RS
Riad Sherif, M.D.
Chief Executive Officer
SC
Sylvia Cheung, CPA
Chief Financial Officer
AM
Arshad M. Khanani, M.D., M.A.
Chief Medical Officer
CA
Christina Ackermann, J.D.
General Counsel & Chief Compliance Officer
DH
David H. Moore, J.D.
Chief Business Officer
MK
Martijn Kleijwegt
Chairman of the Board
PE
Prof. Einar Stefánsson
Board Member, Co-Founder & Co-Inventor of OPTIREACH®